ZNF146-Mediated HMGB1-NF-κB Signaling Activation as a TherapeuticTarget and Prognostic Biomarker in Osteosarcoma
ZNF146 promotes osteosarcoma progression through HMGB1-mediated NF-κB activation, suggesting its potential as both a prognostic biomarker and a therapeutic target. Inhibition of ZNF146 or HMGB1 may offer novel strategies for osteosarcoma treatment.
Authors
- Shenglin Xu (ORCID: https://orcid.org/0000-0002-3055-7227)
- Shaohua Li (ORCID: https://orcid.org/0000-0001-7399-821X)
- Hao Wang (ORCID: https://orcid.org/0000-0001-6881-9977)
- Longze Xiao
- Yong Hu
- Qianxi Wang
- Rui Yang
- Hu Feng
Institutions
- Anhui Medical University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Hefei First People's Hospital (CN)
Publication Details
- Journal
- Recent Patents on Anti-Cancer Drug Discovery
- Published
- 2025-12-24
- DOI
- https://doi.org/10.2174/0115748928387577251118114459
- Primary Topic
- Advanced Glycation End Products research
- Type
- article
- Field-Weighted Citation Impact
- 0.00